Blackstone Commits $750 Million to Fund J&J Retinal Drug Trials
Blackstone commits $750 million to Johnson & Johnson's Phase 3 trials of retinal disease drug OLN324.
Blackstone commits $750 million to Johnson & Johnson's Phase 3 trials of retinal disease drug OLN324.